PDCD1 and neoplasm: Notably, for the first time, we demonstrated that TNFRSF9 expression level in the TI-Tregs can predict response to anti-PD-1 immunotherapy in human non-small cell lung cancer (NSCLC), which verifies functional impact of TNFRSF9 in immune–tumor interactions.